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Prognostic significance of cytosolic phospholipase A2 
expression in patients with colorectal cancer
Young Sun Yoo, Sung Chul Lim
1, Kyung Jong Kim
Departments of Surgery and 
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Purpose: Cyclooxygenase-2 is believed to be an important enzyme in the pathogenesis of colorectal cancer (CRC). Cytosolic 
phospholipase A2 (cPLA2), also, have been suggested to be related to the carcinogenesis of CRC. The aim of this study was to 
investigate cPLA2 expression and its relationship with prognostic significance in CRC. Methods: Eighty-eight patients with 
colorectal cancer who underwent curative surgery were enrolled in this study. cPLA2 was examined in 88 primary CRCs by 
immunohistochemistry and we compared their expression with clinicopathologic findings, recurrence and survival in pa-
tients with CRC. Results: The expression of cPLA2 was positive in 54.5% (48/88). The expression of cPLA2 was not correlated 
with clinicopathologic parameters. However, cPLA2 expression was significantly related with vascular endothelial growth 
factor expression. Kaplan-Meier analysis didn’t show any clinical significance in disease-free survival and overall survival 
according to cPLA2 expression. Conclusion: These results suggest that cPLA2 expression was not associated with the prog-
nosis of CRC. However, further large-scale studies are needed to clarify the prognostic effect of cPLA2 in CRC.
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INTRODUCTION
Colorectal cancer (CRC) is one of the most frequent ma-
lignancies worldwide, and remains the worldwide lead-
ing cause of cancer-related deaths [1,2]. In Korea, it is the 
second or third most common cancer and has shown a 
steep increase in recent decades [3].
Recently, much attention has been focused on the in-
volvement of cyclooxygenase (COX) in tumor develop-
ment and progression [4]. COX is a rate-limiting enzyme 
in the biosynthesis of prostaglandin (PG) from arach-
idonic acid (AA), and two isoforms have been charac-
terized, COX-1 and COX-2. COX-2 is an inducible enzyme, 
but it is known to be constitutively overexpressed and to 
have an oncogenic effect in a variety of cancers, including 
colorectal cancer.
In addition to COX-2, PG production is also directly de-
pendant on the availability of free AA. AA is released from 
membrane glycerophospholipids by fatty acid hydrolysis 
from its sn-2 position by phospholipase A2 (PLA2) and 
further metabolized by COX to produce PGs and throm-
boxanes [5]. PLA2 is a key regulatory enzyme in arach-
idonic acid metabolism, which leads to the synthesis of 
PGs via COX pathways. There are several types of PLA2 in 
human cells. Of these, 85 kDa IVA cytosolic PLA2 (cPLA2) 
has been suggested to be the major intracellular form and Young Sun Yoo, et al.
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to play an essential role in stimulus induced AA release 
coupled with COX-2 [6,7]. Because of this key role of 
cPLA2 in prostaglandin production it has also been sug-
gested to participate in intestinal tumorigenesis. But the 
clinical impact of cPLA2 expression on oncologic out-
comes in CRC is unclear. In our previous data [8], we stud-
ied the impact of cPLA2, 15-prostaglandin dehydrogen-
ase, and COX-2 expression on tumor progression in CRC 
and we demonstrated cPLA2 expression was closely asso-
ciated with COX-2 expression and might have an im-
portant role in tumor progression.
Therefore, as a consecutive study, we investigated the 
survival of patients with CRC to determine the prognostic 
significance with respect to cPAL2 expression status.
METHODS
Patients and tissue samples
Eighty-eight patients who had undergone surgical re-
section for primary sporadic colorectal carcinoma by a sin-
gle colorectal surgeon at the Department of Surgery, 
Chosun University Hospital between March 2002 and 
December 2005 were included in this study . No patient 
had a history of hereditary CRC syndrome or regularly 
used aspirin-like drugs. Patients that received pre-oper-
ative chemotherapy or radiotherapy were not included. 
Enrolled patients were followed up until death or 
December 2008; median post-operative follow-up dura-
tion was 44.16 ± 19.50 months. Thirty eight patients had co-
lon cancer and 50 patients had rectal cancers, and mean 
patient age was 63.97 ± 11.67 years. Samples were graded 
by pathologists according to the pathological features of 
the tumors, i.e., histologic grade, lymph node metastasis, 
distant metastasis, and tumor stage (American Joint 
Committee on Cancer tumor, nodes, metastasis [TNM] 
classification). In all cases, archived H&E stained tissue 
slides were obtained for confirmation of pathological fea-
tures and for the selection of suitable tissue blocks for im-
munohistochemical analysis.
Immunohistochemistry
A universal immunoenzyme polymer method was used 
for immunostaining. Four-μm thick sections were cut 
from formalin-fixed, paraffin-embedded tissue blocks, 
mounted on poly-lysine-coated slides, dewaxed in xylene, 
and rehydrated through a graded ethanol series. After de-
paraffinization, antigen retrieval treatment was per-
formed at 121
oC (autoclave) for 15 minutes in 10 mmol/L 
sodium citrate buffer (pH 6.0), and sections were then 
treated with 3% hydrogen peroxide in methanol solution 
for 20 minutes in order to quench endogenous peroxidase 
activity. Nonspecific bindings were blocked by treating 
slides with Ultra V Block (UltraVision Plus Detection 
System, Thermo Fisher Scientific Inc., Fremont, CA, USA) 
and incubation for 5 minutes at room temperature. The 
primary antibodies used were; mouse monoclonal anti-
body to cPLA2 (1:100 4
oC for overnight; Santa Cruz 
Biotechnology Inc., Santa Cruz, CA, USA) and rabbit poly-
clonal antibody to vascular endothelial growth factor 
(VEGF) (1:100 37
oC for one hour, Santa Cruz Biotechnol-
ogy Inc.). Each slide was washed four times in phosphate 
buffered saline (PBS). Biotinylated goat anti-mouse or 
goat anti-rabbit antibody (UltraVision Plus Detection 
System) was applied and incubated for 5 minutes at room 
temperature. Slides were washed again four times in PBS. 
Streptavidin-Alkaline Phosphate conjugate (UltraVision 
Plus Detection System) was then applied and incubated 
for 5 minutes at room temperature. Slides were washed 
four times in PBS. Fast Red/Naphtol Phosphate substrate 
was applied to the sections for visualization and incubated 
10 to 20 minutes. Sections were counterstained with 
Mayer’s hematoxylin for 20 seconds before air drying and 
coverslipping. Normal mouse serum IgG (Vector Labora-
tories Inc., Burlingame, CA, USA) was used in place of the 
primary antibody as a negative control. Positive control 
tissue was colon cancers and inflammatory cells stained 
positive for cPLA2 and VEGF. All experiments were per-
formed in duplicate.
Immunohistochemical staining
Each slide was assessed by a pathologist unaware of pa-
tient details. For cPLA2, extent of staining was graded as 
follows: 0 - staining in less than 1% of tumor cells; 1 - stain-
ing in 1 to 20%; 2 - staining in 20 to 50%; and 3 - staining in 
more than 50%. Overall intensity of staining was also as-Cytosolic phospholipase A2 in colorectal cancer
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Table 1. Correlation of clinicopathologic parameters with cPLA2 
expressions
Clinicopathologic
cPLA2 (%) P-value
 parameters
All cases 48/88 (54.5)
Sex 0.141
    Male 27/43 (62.8)
    Female 21/45 (46.7)
Age 0.088
　＜60 16/28 (57.1)
　≥60 32/60 (53.3)
Site 0.380
　Colon 23/38 (60.5)
　Rectum 25/50 (50.0)
Depth of invasion 0.301
　pT0   3/10 (30.0)
　pT1/pT2 11/24 (45.8)
　pT3/pT3 34/54 (63.0)
Lymph node metastasis 0.108
　No 21/43 (48.8)
　Yes 23/35 (65.7)
TNM stage 0.189
　0   3/10 (30.0)
　I   8/19 (42.1)
　II 14/24 (58.3)
　III 17/29 (58.6)
　IV     6/6 (100)
Histologic differentiation 0.086
　Well 10/14 (71.4)
　Moderate/Poor 34/59 (57.6)
Pre-operative CEA level 0.139
　Normal 23/49 (46.9)
　Elevated 12/20  (60.0)
Recurrence 0.778
　No 29/55 (52.7)
　Yes 10/16 (62.5)
VEGF expression 0.016
　Negative 11/30 (36.7)
a)
　Positive 36/57  (63.2)
cPLA2, cytosolic phospholipase A2; TNM, tumor, nodes, metasta-
sis; CEA, carcinoembryonic antigen; VEGF, vascular endothelial 
growth factor.
a)Significant: negative VEGF expression vs. positive VEGF 
expression, P = 0.016 (Revised from Lim SC, Cho H, Lee TB, Choi 
CH, Min YD, Kim SS, et al. Yonsei Med J 2010;51:692-9, with 
permission of Yonsei University College of Medicine) [8]. 
sessed as follows: 0 no staining; 1 weak staining; 2 moder-
ate staining; and 3 strong staining. Final scores (range, 
from 0 to 9) were obtained by multiplying staining extents 
and intensities. Final scores were described as follows: 0, 
no expression; 1 to 3, weak expression; 4 to 6, moderate ex-
pression; and 7 to 9, strong expression [7]. For statistical 
analysis, no expression and weak expression were com-
bined and described as negative for expression, and mod-
erate and strong expression were combined and described 
as positive for expression.
VEGF staining was defined as positive when ＞10% of 
tumor cells were stained, and as negative when ≤10% of 
tumor cells were stained [9]. Representative examples of 
cPLA2 in normal tissue and cancer tissue are shown in Fig. 
1.
Statistical analysis 
The χ
2 test and Fisher’s exact probability were used to 
analyze the relationship of cPLA2 according to clin-
icopathologic characteristics and VEGF expression. The 
Kaplan-Meier method was used to estimate survival as a 
function of time and recurrence, survival differences were 
analyzed with the log-rank test. Significance was defined 
as P-values of ＜0.05. The SPSS ver. 17.0 (SPSS Inc., 
Chicago, IL, USA) was used for statistical analysis.
RESULTS
Expression of cPLA2 (Table 1) (revised from our 
previous study [8])
cPLA2 staining was observed in the smooth muscle of 
the muscularis propria and the muscularis mucosa, in 
some superficial interstitial cells, and in rare endothelial 
cells. In normal epithelial cells there was no staining or 
weak cPLA2 staining (Fig. 1A). 
cPLA2 expression was positive in 54.5% (48/88) of tu-
mor samples and was positive in 60.5% (23/38) of colon 
cancers and 50.5% (25/50) of rectal cancers. When classi-
fied by the depth of invasion, cPLA2 expression was pos-
itive in 30.0% (3/10) of pT0, 45.8% (11/24) of pT1/pT2 and 
63.0% (34/54) of pT3/pT4 (P = 0.287). According to the 
lymph node status, cPLA2 expression was positive in 
48.8% of absent lymph node involvement and in 65.7% of 
present lymph node involvement (P = 0.194). According to 
TNM stage, cPLA2 expression was positive in 30.3% (3/10) 
of stage 0, 42.1% (8/19) of stage I, 58.3% (14/24) of stage II, 
58.6% (17/29) of stage III and 100% (6/6) of stage IV (P = 
0.543).Young Sun Yoo, et al.
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Fig. 1. Immunohistochemical staining. (A) Negative cytosolic phospholipase A2 (cPLA2) in normal tissue. (B) Positive cPLA2 in cancer tissue.
Fig. 2. Overall survival (A) and the disease-free survival (B) curves of patients according to the status of cytosolic phospholipase A2 (cPLA2) 
expression.
Also, with regard to pre-operative carcinoembryonic 
antigen (CEA) levels, the positive expression rate of cPLA2 
was 46.9% with normal pre-operative CEA levels and 
60.0% with elevated CEA levels. Although cPLA2 ex-
pression was not significantly related to the clinicopatho-
logic parameters, cPLA2 expression tended to be high in 
patients with an advanced stage or unfavorable clin-
icopathologic features such as pT3/pT4, positive lymph 
node metastasis and elevated pre-operative CEA levels. 
Moreover cPLA2 expression was significantly related to 
VEGF expression (P = 0.016). cPLA2 expression was pos-
itive in 63.2% (36/57) of patients who showed positive 
VEGF expression compared to 36.7% (11/30) of negative 
VEGF expression. 
Correlation with patient survival
For evaluation of patient survival, we precluded stage 0, 
I and IV patients. So we evaluated the survival analysis in 
a total of 55 patients with stage II, and III patients of color-
ectal cancer according to the status of cPLA2 expression.
Five-year overall survival was 70.4% in patients show-
ing positive cPLA2 expression and 72.4% in negative 
cPLA2 expression (P = 0.657). Five-year disease-free sur-
vival was 59.2% in patients showing positive cPLA2 ex-Cytosolic phospholipase A2 in colorectal cancer
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pression and 69.3% in negative cPLA2 expression (P = 
0.360). Using Kaplan-Meier survival analysis, there was no 
statistically significant difference in overall survival rates 
and disease free survival rates according to cPLA2 ex-
pression (Fig. 2). When we investigated the survival rate of 
colon and rectal cancer according to cPLA2 expression re-
spectively, no significant difference was shown, 
statistically.
DISCUSSION
We evaluated the expression profiles of cPLA2 in pa-
tients with colorectal cancer in a previous study. Consecu-
tively, in this study, we tried to demonstrate that the ex-
pression of cPLA2 had prognostic significance in patients 
with colorectal cancer. 
It has been suggested that colonic tumors release free 
AA and usually produce more PGs compared with normal 
mucosa tissue [10]. cPLA2 is a key enzyme for PGs and 
cPLA2 involvement in intestinal tumorigenesis has been 
suggested. For the first time, Soydan et al. [11] demon-
strated that human colon tumors and associated normal 
mucosa and submucosa contain high molecular weight 
cPLA2. Other studies have already reported over-
expression of cPLA2 found in 35 to 50% of CRC [7,12]. We 
found that cPLA2 was overexpressed in 54.5% of tissue 
sample tested but cPLA2 expression was not related to 
other clinicopathologic parameters, except for VEGF 
expression. VEGF expression showed a statistically sig-
nificant correlation with cPLA2 expression (P = 0.016). 
These results strongly suggest that cPLA2 plays an im-
portant role in tumor development and progression in 
CRC. Similar to our study, it was reported that there was 
an association between a high number of cPLA2 positive 
stromal cells and a strong VEGF expression [13]. 
cPLA2 expression in animal models has been suggested 
t o  b e  p r o - t u m o u r i g e n i c .  H o m o z y g o u s  d e l e t i o n  o f  t h e  
cPLA2 gene in mice was found to dramatically reduce 
small intestinal polyp development but not colonic polyp 
development, suggesting that cPLA2 had an oncologic ef-
fect and a role in tumor promotion [14,15]. On the other 
hand, in azoxymethane-induced mouse models, down 
regulation of cPLA2 attenuated tumor necrosis factor-al-
pha mediated apoptosis and facilitated tumor progression 
[16]. Furthermore, knock-out of cPLA2 was found to en-
hance tumorigenesis in mice, suggesting a proapoptotic 
role of cPLA2 expression [17].
As shown in animal models, there are highly variable 
results on cPLA2 expression in human CRC. Some have 
suggested that cPLA2 is overexpressed [11-13,18], others, 
on the other hand, have concluded to the contrary [19]. 
Furthermore, in another study, researchers reported that 
the role of cPLA2 seems not to be the rate-limiting step in 
PGs formation and cPLA2 plays a minor or no role in hu-
man colorectal carcinogenesis [20].
One previous study showed that acetylsalicylic acid-in-
duced downregulation of cPLA2 expression supports 
growth inhibition and apoptosis in colon cancer cells [21]. 
Panel et al. [7] reported that, in immunohistochemistry of 
65 patients with colorectal cancers and Western blot of sev-
eral colorectal cancer cell lines, cPLA2 was overexpressed 
in about half of the cases, and that cPLA2 expression was 
correlated with COX-2 expression, which strongly sug-
gests that cPLA2 plays an important role in tumor devel-
opment and progression in CRC. But other studies 
showed that cPLA2 plays an important role in tumor ne-
crosis factor α-induced apoptosis in human colon cancer 
cells and that colon cancer growth is favored when intra-
cellular AA levels are suppressed by inhibition of cPLA2 
[19].
None of these studies have demonstrated the prog-
nostic effect of cPLA2 expression in patients with CRC. 
Regarding patient survival and cPLA2 expression, we 
found that cPLA2 expression in CRC was not associated 
with patient survival. This is the first investigation in 
which survival of patients is evaluated according to cPLA2 
expression in CRC. There was only one report in which 
quantification of group IIA PLA2, not cPLA2, expression 
seems to provide valuable prognostic information in stage 
II CRC [22].
Alterations in the levels and activity of cPLA2 have been 
associated with cancer pathogenesis in other organs. 
cPLA2 expression is increased in several human cancers 
including small bowel, lung, bile duct and liver [12,23-25]. 
Proliferation of prostate cancer is also dependant on the Young Sun Yoo, et al.
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action of cPLA2 [26].
In conclusion, these results suggest that cPLA2 is con-
stitutively overexpressed and might have an important 
role in tumor progression. However, cPLA2 expression 
does not seem to play a role in the prognosis of CRC. 
Further large scaled studies are needed to clarify the prog-
nostic effect of cPLA2 in CRC.
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